《新股》中慧生物(02627.HK)今起招股 入場費3,131.26元
疫苗公司江蘇中慧元通生物科技(02627.HK)在港進行首次公開發售(IPO),計劃全球發售3,344.26萬股H股,香港公開發售佔10%(約334.44萬股),國際配售部分佔90%(3,009.82萬股),發售價介乎每股12.9至15.5元,最多集資約5.18億元。每手買賣單位200股,入場費約3,131.26元。
招股期由今日(31日)起至下周二(8月5日)止,預計將於8月8日掛牌上市,由中信証券及招銀國際擔任聯席保薦人。按發售價中位價14.2元計,集資所得淨額約4.21億元,其中約63.6%將用於核心產品的開發及國內外註冊,約18.1%用於其他在研疫苗的開發和註冊,約8.4%用於改進工藝及商業化能力,約4.9%用於技術平台的開發,餘下5%作營運資金及其他一般公司用途。
是次IPO引入嘉興鑫揚及華泰資本投資為基石投資者,將認購約1,300萬美元等值股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.